IMV Inc.
IMV
Ранг среди акций
#35144
IMV Inc. is a clinical-stage biotechnology company dedicated to the development... IMV Inc. is a clinical-stage biotechnology company dedicated to the development of innovative immunotherapies. The company utilizes its proprietary DPX immune-educating technology platform to create a portfolio of treatments for various solid and hematological cancers. Its leading investigational drug, maveropepimut-S, is a DPX-based immunotherapy designed to target cancer cells that express survivin. Maveropepimut-S is currently undergoing Phase II clinical trials for diffuse large B-cell lymphoma, ovarian cancer, and specific bladder, liver, and microsatellite instability-high tumors, with Phase I trials also active for breast cancer. Beyond its primary candidate, IMV is also advancing DPX-SurMAGE, which is in Phase I clinical trials for bladder cancer, and is developing DPX-COVID-19 and DPX-RSV to address infectious diseases. Originally founded in 2000 as Immunovaccine Inc., the company adopted the name IMV Inc. in May 2018 and operates from its headquarters in Dartmouth, Canada.
Цена акции
$0.82959892
Последняя синхронизация: 2023-05-23
Рыночная капитализация
$4.16M
Изменение (1 день)
-0.04%
Изменение (1 год)
82,959,792.06%
Страна
CA
Торговля IMV Inc. (IMV)
Категория
Healthcare
История дроблений акций IMV Inc. (IMV)
Акции IMV Inc. (символ: IMV) прошли через 0 дроблений.
Последнее дробление произошло Oct 21, 2026.
Одна акция IMV, купленная до Oct 21, 2026, сейчас соответствует 0 акциям IMV.
Последнее дробление произошло Oct 21, 2026.
Одна акция IMV, купленная до Oct 21, 2026, сейчас соответствует 0 акциям IMV.
Список дроблений акций
| Год | Дробление | Коэффициент | Суммарный коэффициент |
|---|---|---|---|
| Недостаточно данных для указанных дат. | |||
Дробления акций аналогичных компаний или конкурентов
| Компания | Количество дроблений акций | Суммарный коэффициент | Страна |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
